Compare AGCO Corporation (AGCO) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs ARK Genomic Revolution ETF — how do they compare? AGCO Corporation trades at $101.37 (market cap $7.10B), while ARK Genomic Revolution ETF trades at $44.62. The key difference: AGCO Corporation pays a 1.18% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, AGCO Corporation nearer its low. Which is the better fit depends on your goals.
| AGCO | ARKG | |
|---|---|---|
Market Cap | $7.10B | — |
Sector | Industrials | Sector/Thematic |
52-Week High | $140.49 | $44.55 |
52-Week Low | $100.14 | $24.02 |
Enterprise Value | $9.37B | — |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $101.55, up 0.67% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed estimates, leading to an 11% share drop and multiple legal investigations. The company maintains a solid balance sheet with $612M cash and a 5.15% net income margin, but faces headwinds from lowered 2026 guidance and weak agricultural demand.
The outlook is cautious; while valuation ratios like P/E of 14.03 appear attractive and analysts set a $124.63 consensus target, risks from earnings volatility, legal scrutiny, and industry softness outweigh near-term opportunities. Investors should weigh the dividend yield against potential further downside from ongoing investigations and macroeconomic pressures.
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
